Patent EP0108218A2 successfully refreshed from Google Patents.
EP0108218A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility
Assignee: Verex Laboratories Inc
•
Filing: 1983-09-12
•
Granted: —
•
Expires: 2003-09-12
Abstract
Abstract The present invention provides constant order release tablets of drugs which have a high degree of water-solubility. The tablet formulations of this invention comprise: a therapeutically effective amount of a drug having a high degree of water solubility, from about 8-18 weight percent of an acrylic acid polymer; from about 8-18 weight percent of polyethylene glycol having a molecular weight of from 4000-6000; from about 2 to 9 weight percent of a hydrogenated vegetable oil; from about 0.5 to 3 weight percent of fumed silicon dioxide; from about 15 to 25 weight percent of a disintegrant; from about 20 to 40 weight percent of a diluent; and from 0.5 to 2 weight percent of a lubricant.
Inventors
- 👤 James Michael Dunn
- 👤 Ronald Thomas Haas
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 19:38
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
129 words
A constant order release formulation of a drug having a high degree of water solubility in tablet unit dosage form, said tablet comprising: a therapeutically effective amount of a highly water-soluble drug; from about 8 to 18 weight percent of a first dissolution retardant, said dissolution retardant being an acrylic acid polymer; from about 8 to 18 weight percent of a second dissolution retardant, said second retardant selected from the group consisting of polyethylene glycol having a molecular weight of from 4000-6000, inclusive, and a cellulosic derivative; from about 15 to 25 weight percent of a disintegrant; from about 20 to 40 weight percent of a diluent; from about 0.5 to 3 weight percent of fumed silicon dioxide; and from about 0.5 to 2.0 weight percent of a lubricant.
Claim 2
Dependent Claim
129 words
A constant order release formulation of a drug having a high degree of water solubility in tablet unit dosage form, said tablet comprising: a therapeutically effective amount of a highly water-soluble drug; from about 8 to 18 weight percent of a first dissolution retardant, said dissolution retardant being an acrylic acid polymer; from about 8 to 18 weight percent of a second dissolution retardant, said second retardant selected from the group consisting of polyethylene glycol having a molecular weight of from 4000-6000, inclusive, and a cellulosic derivative; from about 15 to 25 weight percent of a disintegrant; from about 20 to 40 weight percent of a diluent; from about 0.5 to 3 weight percent of fumed silicon dioxide; and from about 0.5 to 2.0 weight percent of a lubricant.
Claim 3
Dependent Claim
20 words
The tablet of claim 1 wherein said second retardant is polyethylene glycol having a molecular weight of from 4000-6000 inclusive.
Claim 4
Dependent Claim
22 words
The tablet of claim 1 wherein said formulation additionally comprises from about 2 to 9 weight percent of a hydrogenated vegetable oil.
Claim 5
Dependent Claim
20 words
The tablet of claim 3 wherein said second retardant is polyethylene glycol having a molecular weight of from 4000-6000 inclusive.
Claim 6
Dependent Claim
13 words
The tablet of claim 4 wherein said bulking agent is dibasic calcium phosphate.
Claim 7
Dependent Claim
10 words
The tablet of claim 5 wherein said disintegrant is lactose.
Claim 8
Dependent Claim
32 words
The tablet of claim 2 wherein said acrylic acid polymer is Carbopol-934P carbomer, said hydrogenated vegetable oil is hydrogenated cottonseed oil, said.disintegrant is lactose and said bulking agent is dibasic calcium phosphate.
Claim 9
Dependent Claim
11 words
The tablet of claim 7 wherein said water-soluble drug is phenylpropanolamine.
Claim 10
Dependent Claim
11 words
The tablet of claim 7 wherein said active drug is chlorpheniramine.
Claim 11
Dependent Claim
12 words
The tablet of claim 7 wherein said active drug is isosorbide dinitrate.
Claim 12
Dependent Claim
16 words
The tablet of claim 7 wherein said water-soluble drug is a combination of phenylpropanolamine and chlorpheniramine.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.